Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

BACKGROUND: Current approaches for treating metastatic malignant melanoma (MM) are not effective enough and are associated with serious adverse events. Due to its immunogenicity, melanoma is an attractive target for immunostimulating therapy. In this phase I/IIa study, local AdCD40L immunostimulator...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Loskog, Angelica, Maleka, Aglaia, Mangsbo, Sara, Svensson, Emma, Lundberg, Christina, Nilsson, Anders, Krause, Johan, Agnarsdóttir, Margrét, Sundin, Anders, Ahlström, Håkan, Tötterman, Thomas H, Ullenhag, Gustav
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4984796/
https://ncbi.nlm.nih.gov/pubmed/27031851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.42
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados